Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

Casimiro-Garcia A, Filzen GF, Flynn D, Bigge CF, Chen J, Davis JA, Dudley DA, Edmunds JJ, Esmaeil N, Geyer A, Heemstra RJ, Jalaie M, Ohren JF, Ostroski R, Ellis T, Schaum RP, Stoner C.

J Med Chem. 2011 Jun 23;54(12):4219-33. doi: 10.1021/jm200409s. Epub 2011 May 26.

PMID:
21557540
2.

Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

Casimiro-Garcia A, Heemstra RJ, Bigge CF, Chen J, Ciske FA, Davis JA, Ellis T, Esmaeil N, Flynn D, Han S, Jalaie M, Ohren JF, Powell NA.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):767-72. doi: 10.1016/j.bmcl.2012.11.088. Epub 2012 Dec 1.

PMID:
23265881
3.

Synthesis and evaluation of novel nonpeptide angiotensin II receptor antagonists: imidazo[4,5-c]pyridine derivatives with an aromatic substituent.

Kiyama R, Fuji M, Hara M, Fujimoto M, Kawabata T, Nakamura M, Fujishita T.

Chem Pharm Bull (Tokyo). 1995 Mar;43(3):450-60.

PMID:
7774028
4.

Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.

Mizuno CS, Chittiboyina AG, Shah FH, Patny A, Kurtz TW, Pershadsingh HA, Speth RC, Karamyan VT, Carvalho PB, Avery MA.

J Med Chem. 2010 Feb 11;53(3):1076-85. doi: 10.1021/jm901272d.

PMID:
20073471
6.
7.

Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.

Cappelli A, Pericot Mohr Gl Gl, Gallelli A, Rizzo M, Anzini M, Vomero S, Mennuni L, Ferrari F, Makovec F, Menziani MC, De Benedetti PG, Giorgi G.

J Med Chem. 2004 May 6;47(10):2574-86.

PMID:
15115399
8.

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF.

Vascul Pharmacol. 2006 Sep;45(3):154-62. Epub 2006 May 16.

PMID:
16765099
9.

Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.

J Med Chem. 2011 Dec 22;54(24):8541-54. doi: 10.1021/jm201061j. Epub 2011 Nov 28.

PMID:
22070604
10.

Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.

Nie YY, Da YJ, Zheng H, Yang XX, Jia L, Wen CH, Liang LS, Tian J, Chen ZL.

Bioorg Med Chem. 2012 Apr 15;20(8):2747-61. doi: 10.1016/j.bmc.2012.02.003. Epub 2012 Feb 11.

PMID:
22410249
11.

Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.

Dhanoa DS, Bagley SW, Chang RS, Lotti VJ, Chen TB, Kivlighn SD, Zingaro GJ, Siegl PK, Patchett AA, Greenlee WJ.

J Med Chem. 1993 Dec 24;36(26):4230-8.

PMID:
8277505
12.

Dihydropyrimidine angiotensin II receptor antagonists.

Atwal KS, Ahmed SZ, Bird JE, Delaney CL, Dickinson KE, Ferrara FN, Hedberg A, Miller AV, Moreland S, O'Reilly BC, et al.

J Med Chem. 1992 Dec 11;35(25):4751-63.

PMID:
1469703
13.

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.

Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.

Arch Pharm Res. 2009 May;32(5):721-7. doi: 10.1007/s12272-009-1511-8. Epub 2009 May 27.

PMID:
19471887
14.

Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.

Rikimaru K, Wakabayashi T, Abe H, Tawaraishi T, Imoto H, Yonemori J, Hirose H, Murase K, Matsuo T, Matsumoto M, Nomura C, Tsuge H, Arimura N, Kawakami K, Sakamoto J, Funami M, Mol CD, Snell GP, Bragstad KA, Sang BC, Dougan DR, Tanaka T, Katayama N, Horiguchi Y, Momose Y.

Bioorg Med Chem. 2012 May 15;20(10):3332-58. doi: 10.1016/j.bmc.2012.03.036. Epub 2012 Mar 23.

PMID:
22503460
15.

Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.

Xu Y, Etgen GJ, Broderick CL, Canada E, Gonzalez I, Lamar J, Montrose-Rafizadeh C, Oldham BA, Osborne JJ, Xie C, Shi Q, Winneroski LL, York J, Yumibe N, Zink R, Mantlo N.

J Med Chem. 2006 Sep 21;49(19):5649-52.

PMID:
16970391
16.

A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.

Chakravarty PK, Naylor EM, Chen A, Chang RS, Chen TB, Faust KA, Lotti VJ, Kivlighn SD, Gable RA, Zingaro GJ, et al.

J Med Chem. 1994 Nov 25;37(24):4068-72. No abstract available.

PMID:
7990105
17.

Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.

Cappelli A, Nannicini C, Gallelli A, Giuliani G, Valenti S, Mohr Gl, Anzini M, Mennuni L, Ferrari F, Caselli G, Giordani A, Peris W, Makovec F, Giorgi G, Vomero S.

J Med Chem. 2008 Apr 10;51(7):2137-46. doi: 10.1021/jm7011563. Epub 2008 Mar 5.

PMID:
18318468
18.

Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.

Keil S, Matter H, Schönafinger K, Glien M, Mathieu M, Marquette JP, Michot N, Haag-Diergarten S, Urmann M, Wendler W.

ChemMedChem. 2011 Apr 4;6(4):633-53. doi: 10.1002/cmdc.201100047. Epub 2011 Mar 11.

PMID:
21400663
19.

Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.

Otake K, Azukizawa S, Fukui M, Kunishiro K, Kamemoto H, Kanda M, Miike T, Kasai M, Shirahase H.

Bioorg Med Chem. 2012 Jan 15;20(2):1060-75. doi: 10.1016/j.bmc.2011.11.035. Epub 2011 Dec 1.

PMID:
22197396
20.

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, Grover G, Harrity T, Ma Z, Moore L, Ren J, Seethala R, Cheng L, Sleph P, Sun W, Tieman A, Wetterau JR, Doweyko A, Chandrasena G, Chang SY, Humphreys WG, Sasseville VG, Biller SA, Ryono DE, Selan F, Hariharan N, Cheng PT.

J Med Chem. 2005 Mar 24;48(6):2248-50.

PMID:
15771468
Items per page

Supplemental Content

Write to the Help Desk